Zhou Qingyu, Chan Eli
Department of Pharmacy, National University of Singapore, 18 Science Drive 4, Singapore 117543, Singapore.
Eur J Pharm Sci. 2002 Oct;17(1-2):73-80. doi: 10.1016/s0928-0987(02)00148-3.
The interaction between the antineoplastic agent 5-fluorouracil (5-FU) and the oral anticoagulant warfarin enantiomers was investigated in rats. An increase in hypoprothrombinaemic response, assessed by means of percent changes of prothrombin complex activity and clotting factor VII activity, to warfarin, was observed following oral administration of 1.5 mg/kg racemic warfarin to rats during a 8-day intraperitoneal dose regimen of 5-FU (13.3 mg/kg daily). 5-FU had no apparent effect on the baseline blood coagulation, the in vitro rat serum protein binding as well as the absorption and distribution of the S- and R-enantiomers of warfarin in rats. Yet treatment with 5-FU produced a significant decrease in the total serum clearance value of S-warfarin in rats. The decreased total clearance was attributed mainly to a significant decrease in the formation rate of the overall oxidative metabolites of the more potent S-enantiomer of warfarin.
在大鼠中研究了抗肿瘤药物5-氟尿嘧啶(5-FU)与口服抗凝剂华法林对映体之间的相互作用。在5-FU(每日13.3mg/kg)连续8天腹腔给药期间,给大鼠口服1.5mg/kg消旋华法林后,观察到通过凝血酶原复合物活性和凝血因子VII活性的百分比变化评估的华法林低凝血酶原血症反应增加。5-FU对大鼠的基线血液凝固、体外大鼠血清蛋白结合以及华法林S-和R-对映体在大鼠体内的吸收和分布没有明显影响。然而,用5-FU治疗会使大鼠体内S-华法林的总血清清除值显著降低。总清除率降低主要归因于华法林更有效的S-对映体的整体氧化代谢物形成速率显著降低。